Towarzystwo Funduszy Inwestycyjnych PZU SA Lowers Stock Holdings in Amgen Inc. $AMGN

Towarzystwo Funduszy Inwestycyjnych PZU SA lowered its holdings in Amgen Inc. (NASDAQ:AMGN) by 54.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 2,262 shares of the medical research company’s stock after selling 2,673 shares during the period. Towarzystwo Funduszy Inwestycyjnych PZU SA’s holdings in Amgen were worth $740,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Twin City Private Wealth LLC grew its position in shares of Amgen by 0.8% in the fourth quarter. Twin City Private Wealth LLC now owns 4,316 shares of the medical research company’s stock valued at $1,413,000 after purchasing an additional 33 shares during the period. Tamar Securities LLC grew its position in shares of Amgen by 15.9% in the fourth quarter. Tamar Securities LLC now owns 81,341 shares of the medical research company’s stock valued at $26,624,000 after purchasing an additional 11,143 shares during the period. USS Investment Management Ltd grew its position in Amgen by 1.0% during the fourth quarter. USS Investment Management Ltd now owns 91,350 shares of the medical research company’s stock valued at $29,907,000 after acquiring an additional 921 shares during the period. WealthTrust Axiom LLC grew its position in Amgen by 0.6% during the fourth quarter. WealthTrust Axiom LLC now owns 5,149 shares of the medical research company’s stock valued at $1,685,000 after acquiring an additional 33 shares during the period. Finally, Vanguard Personalized Indexing Management LLC grew its position in Amgen by 23.0% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 88,290 shares of the medical research company’s stock valued at $28,898,000 after acquiring an additional 16,515 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen said its phase 3 ABP 938 eye-disease study is advancing, with the drug aimed at challenging Regeneron’s Eylea HD in a major retina market. That keeps Amgen’s pipeline in focus as a potential future growth driver. Article Title
• Positive Sentiment: Amgen also highlighted its MARITIME-SWITCH phase 3 obesity trial, which is designed to capture GLP-1 switchers. Any success in obesity treatment could open another large market and improve long-term revenue expectations. Article Title
• Positive Sentiment: Some coverage pointed to Amgen as a value stock with supportive new data from the VESALIUS-CV cardiovascular study for Repatha, reinforcing confidence in the company’s broader portfolio. Article Title
• Neutral Sentiment: Amgen and outside analysts published bullish commentary on the stock’s valuation and earnings profile, but these were mostly opinion pieces rather than new business developments. Article Title
• Negative Sentiment: Investor sentiment is being pressured by reports that Amgen’s Tavneos faces a proposed FDA withdrawal, with the company seeking a hearing and commissioning an independent review to defend the drug’s data. Regulatory uncertainty around a $500 million product is a meaningful risk for the stock. Article Title
• Negative Sentiment: Reuters also reported that Amgen hired a research firm to reassess Tavneos data after FDA concerns, underscoring the regulatory overhang and near-term uncertainty for the drug. Article Title

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of research reports. Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Leerink Partners reissued a “market perform” rating and set a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research report on Sunday. Daiwa Securities Group lowered their price target on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Finally, Royal Bank Of Canada boosted their price target on Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $354.12.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

Amgen Stock Performance

Shares of AMGN opened at $355.20 on Monday. The stock’s 50-day moving average is $340.97 and its two-hundred day moving average is $345.80. The stock has a market cap of $191.70 billion, a PE ratio of 24.72, a P/E/G ratio of 3.56 and a beta of 0.42. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.